Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The participant had CKD requiring dialysis or CKD not on dialysis with an estimated glomerular filtration rate (GFR) \<60 mL/min/1.73 m\^2 based on central laboratory results.~* The participant had a serum phosphorus level greater than the age appropriate upper limit of normal based on central laboratory results.~Exclusion Criteria:~* The participant had active dysphagia, swallowing disorders or a predisposition to or current bowel obstruction, ileus or severe gastrointestinal motility disorder(s) including severe constipation, or major gastrointestinal tract surgery.~* The participant had a non-renal case of hyperphosphatemia.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- FDP-Placebo for Sevelamer Carbonate, DTP-Sevelamer Carbonate (Type: PLACEBO_COMPARATOR): Participants received placebo for 2 weeks during the fixed dose period (FDP). Participants received sevelamer carbonate for 26 weeks in dose titration period (DTP).
- FDP-Sevelamer Carbonate, DTP-Sevelamer Carbonate (Type: EXPERIMENTAL): Participants received sevelamer carbonate for 2 weeks during the FDP of the study. Participants received sevelamer carbonate for an additional 26 weeks in DTP.

Based on this trial design, predict the completion outcome and termination type (if applicable).